이수진

This profile gathers the share dealings of 이수진 in 압타바이오. We count 7 filings; the first trade dates from 25 August 2021 and the latest from 28 April 2023.

No open-market sale appears; the market trades are 6 purchases worth €1.1M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. So far in 2023, the count stands at 6 purchases and no sales.

Half of the purchases are above €114k and half below. Of 6 purchases, 6 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

On 8 May 2023 came the latest disclosure, an open-market purchase for €54k in 압타바이오. Between a trade and the moment it shows up on DART (FSS), the median delay is 4 days. Until a filing is published, the market cannot know about the trade. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.